Keytruda, Opdivo Set To Challenge Tecentriq In Bladder Cancer
Executive Summary
Phase III trial of Merck's Keytruda stops early with survival benefit as FDA accepts filing of Bristol's Opdivo, which has breakthrough therapy status and priority review.